<DOC>
	<DOC>NCT00374907</DOC>
	<brief_summary>The purpose of this clinical research study is to learn whether Saxagliptin can improve the body's ability to make its own insulin and lower blood sugar in people with type 2 diabetes</brief_summary>
	<brief_title>A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise</brief_title>
	<detailed_description>All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to receive open-label metformin added onto their blinded study medication</detailed_description>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus Drug naive Hemoglobin A1c (HbA1c) ≥6.0% and ≤8.0% Fasting Cpeptide ≥1.0 ng/mL Body mass index ≤40 kg/m² Recent cardiac or cerebrovascular event Elevated serum creatinine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>